{
  "id": "601c287f1cb411341a000012",
  "type": "list",
  "question": "Which transporter is inhibited by Sotagliflozin?",
  "ideal_answer": "Sotagliflozin, a dual inhibitor of sodium-glucose co-transporters 1 and 2.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31064765",
    "http://www.ncbi.nlm.nih.gov/pubmed/30819210",
    "http://www.ncbi.nlm.nih.gov/pubmed/33108240",
    "http://www.ncbi.nlm.nih.gov/pubmed/29916741",
    "http://www.ncbi.nlm.nih.gov/pubmed/26548423",
    "http://www.ncbi.nlm.nih.gov/pubmed/28387957",
    "http://www.ncbi.nlm.nih.gov/pubmed/31172412",
    "http://www.ncbi.nlm.nih.gov/pubmed/32717480",
    "http://www.ncbi.nlm.nih.gov/pubmed/33413413",
    "http://www.ncbi.nlm.nih.gov/pubmed/29212386",
    "http://www.ncbi.nlm.nih.gov/pubmed/29637608",
    "http://www.ncbi.nlm.nih.gov/pubmed/31468649",
    "http://www.ncbi.nlm.nih.gov/pubmed/31837264",
    "http://www.ncbi.nlm.nih.gov/pubmed/29937430",
    "http://www.ncbi.nlm.nih.gov/pubmed/34106300",
    "http://www.ncbi.nlm.nih.gov/pubmed/32567125",
    "http://www.ncbi.nlm.nih.gov/pubmed/25690134",
    "http://www.ncbi.nlm.nih.gov/pubmed/33289297",
    "http://www.ncbi.nlm.nih.gov/pubmed/31850616",
    "http://www.ncbi.nlm.nih.gov/pubmed/33179277",
    "http://www.ncbi.nlm.nih.gov/pubmed/28899222",
    "http://www.ncbi.nlm.nih.gov/pubmed/31761990",
    "http://www.ncbi.nlm.nih.gov/pubmed/26049551",
    "http://www.ncbi.nlm.nih.gov/pubmed/34232488",
    "http://www.ncbi.nlm.nih.gov/pubmed/31942549"
  ],
  "snippets": [
    {
      "text": "CONTEXT: The effect of sotagliflozin (a dual sodium-glucose cotransporter [SGLT] 2 and SGLT1 inhibitor) on intestinal glucose absorption has not been investigated in humans.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31837264",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The potential of this method is showcased by the preparation and diversification of sotagliflozin, leading to the discovery of a promising SGLT2 inhibitor candidate.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31850616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Compared with metformin at Week 24 to 26, the SGLT inhibitors dapagliflozin (5 mg), sotagliflozin (200\u2009mg) and empagliflozin (10 mg) had larger reductions in HbA1c (mean difference [MD] = -0.24, 95% credible interval [CrI], -0.41 to -0.07, MD = -0.23, 95% CrI, -0.39 to -0.08 and MD = -0.35, 95% CrI, -0.51 to -0.19, respectively) and in weight, which were sustained in sensitivity analyses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31468649",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Global trials have been conducted with liraglutide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and sotagliflozin, an inhibitor of both SGLT1 and SGLT2 transporters.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32567125",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several SGLT2 inhibitors and their derivatives such as remogliflozin etabonate (phase-II), sotagliflozin (phase-III) and bexagliflozin (phase-III) are under different phases of clinical trial studies and some have been patented. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32717480",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin, a dual inhibitor of sodium-glucose co-transporters 1 and 2, has been recently approved for use in patients with T1DM.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33108240",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dapagliflozin (SGLT-2 inhibitor) and sotagliflozin (SGLT1/2 inhibitor) are two of the drugs of SGLT inhibitor class which have been recommended by the National Institute for Health and Care Excellence (NICE) in people with type 1 diabetes with BMI \u226527\u00a0kg/m2 . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33179277",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several clinical trials have shown that sotagliflozin (SGLT1-1/2 inhibitor) decreases body weight and reduces blood pressure in adults with T2D.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31942549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ite a weaker effect on UGE than selective SGLT2 inhibitors, sotagliflozin is as effective as SGLT2 inhibitors on HbA1C reduction, with a similar safety profile in short-term studies. Whi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin appeared more promising for SGLT2 as well as AChE-inhibition with reference to \u0394G and Ki values in comparison to Ertugliflozin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28387957",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin is an oral potent dual inhibitor of the insulin-independent SGLT1 and SGLT2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29916741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "EAS COVERED: Herein, the authors focus specifically on sotagliflozin (LX4211), the first-in-class dual SGLT1/SGLT2 inhibitor. O",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, sotagliflozin (LX4211) has been developed as a dual inhibitor of SGLT1 and SGLT2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25690134",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin (Zynquista\u2122) is a dual inhibitor of sodium-glucose co-transporters (SGLT) 1 and 2 being developed by Lexicon Pharmaceuticals and Sanofi as a treatment for type 1 (T1DM) and type 2 diabetes mellitus (T2DM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31172412",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin (Zynquista\u2122) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31761990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25690134",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Sotagliflozin is a dual sodium-glucose co-transporter (SGLT) 2 inhibitor, manifesting a 20-fold higher inhibitory activity for SGLT2 than for SGLT1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34232488",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30819210",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Global trials have been conducted with liraglutide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and sotagliflozin, an inhibitor of both SGLT1 and SGLT2 transporters.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32567125",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin is a dual sodium-glucose co-transporter (SGLT) 2 inhibitor, manifesting a 20-fold higher inhibitory activity for SGLT2 than for SGLT1. D",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34232488",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for u",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29212386",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIMS: To evaluate the evidence for the novel dual sodium-glucose co-transporter-1 (SGLT1) and -2 (SGLT2) inhibitor, sotagliflozin, which may enhance the efficacy of SGLT2 inhibitors by additionally reducing intestinal glucose absorption",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29637608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). So",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30819210",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabe",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29937430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ation. Sotagliflozin, a dual inhibitor of sodium-glucose co-transporters 1 and 2, has been recently approved for use in patients with",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33108240",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1/SGLT2 inhibitor, is currently approved in Europe as an adjunct to optimal insulin therapy in adults with type 1 diabetes (T1D) and a body mass index (BMI) \u2265\u200927\u2009kg/m2 . In ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33289297",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ls have been conducted with liraglutide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and sotagliflozin, an inhibitor of both SGLT1 and SGLT2 transporters. While dapaglifloz",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32567125",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ion. We investigated the effects of chronic treatment with the dual SGLT-1&2 inhibitor sotagliflozin on left atrial (LA) remodeling and cellular arrhythmogenesis (i.e. atrial cardiomyopathy) in a metabolic syndrome-related rat model of HFpE",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33413413",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "lc5a1) and Sglt2 (also known as Slc5a2) knockout mice were employed to develop sotagliflozin, a dual SGLT1/SGLT2 inhibitor having success in clinical trials for diabe",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31064765",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " the DAPA-CKD study and the SCORED study two different sodium-glucose linked transporter 2 (SGLT2) inhibitors (dapagliflozin and sotagliflozin) were found to improve the prognosis of patients with chronic kidney diseases with and without diabetes. The ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34106300",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "re, sotagliflozin (LX4211) has been developed as a dual inhibitor of SGLT1 and SGLT2. The diff",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25690134",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30819210",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Sotagliflozin inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors) and intestinal SGLT-1, delaying glucose absorption and therefore reducing post prandial glucose.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30819210",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1/SGLT2 inhibitor, is currently approved in Europe as an adjunct to optimal insulin therapy in adults with type 1 diabetes (T1D) and a body mass index (BMI) \u2265\u200927\u2009kg/m2 .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33289297",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29637608",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes.RESEARCH DESIGN AND METHODS: We treated 33 patients with sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, or placebo in a randomized, double-blind trial assessing safety, insulin dose, glycemic control, and other metabolic parameters over 29 days of treatment.RESULTS: In the sotagliflozin-treated group, the percent reduction from baseline in the primary end point of bolus insulin dose was 32.1% (P = 0.007), accompanied by lower mean daily glucose measured by continuous glucose monitoring (CGM) of 148.8 mg/dL (8.3 mmol/L) (P = 0.010) and a reduction of 0.55% (5.9 mmol/mol) (P = 0.002) in HbA1c compared with the placebo group that showed 6.4% reduction in bolus insulin dose, a mean daily glucose of 170.3 mg/dL (9.5 mmol/L), ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIMS: To evaluate the evidence for the novel dual sodium-glucose co-transporter-1 (SGLT1) and -2 (SGLT2) inhibitor, sotagliflozin, which may enhance the efficacy of SGLT2 inhibitors by additionally reducing intestinal glucose absorption.METHODS: The search terms 'sotagliflozin', 'LX4211', 'SGLT' and 'diabetes' were enter",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29637608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index \u2265\u200927\u2009kg/m2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33289297",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "rapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes.METHODS: In this phase 3, double-blind trial, which was conducted at 133 centers worldwide, we randomly assigned 1402 patients with type 1 diabetes who were receiving treatment with any insulin therapy (pump or injections) to receive sotagliflozin (400 mg per day) or ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28899222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONTEXT: The effect of sotagliflozin (a dual sodium-glucose cotransporter [SGLT] 2 and SGLT1 inhibitor) on intestinal glucose absorption has not been investigated in humans.OBJECTIVE: To measure rate of appearance of oral glucose (RaO) using a dual glucose tracer method following standardized mixed meals taken after single sotagliflozin or canagliflozin doses.SETTING: Clinical research organization.DESIGN AND PARTICIPANTS: In a double-blind, 3-period crossover study (NCT01916863), 24 healthy partici",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31837264",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabetes (T1D).RESEARCH DESIGN AND METHODS: The inTandem1 trial, a double-blind, 52-week phase 3 trial, randomized North American adults with T1D to placebo (n = 268), sotagliflozin 200 mg (n = 263), or sotagliflozin 400 mg (n = 262",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29937430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "n, as well as by increasing GLP-1 secretion. Despite a weaker effect on UGE than selective SGLT2 inhibitors, sotagliflozin is as effective as SGLT2 inhibitors on HbA1C reduction, with a ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "as the basis of this review. Clinical trials were identified using the Clinicaltrial.gov database.EXPERT OPINION: By a potential additional mechanism of action on intestinal glucose absorption linked to SGLT1 inhibition, sotagliflozin differentiates from SGLT2 inhibitors by reducing postprandial glucose excursion and insulin secreti",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548423",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "sodium-glucose co-transporter 1, sodium-glucose co-transporter 2"
}